Although more extensive tolerability data are still pending, this assumption is also supported by several successfully completed phase I/II clinical trials in various types of cancers with AT-101, a small molecule simultaneously targeting MCL1, BCL2 and BCL-xL [7]. This evidence concerns the gene BCL2 and cancer.